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Eduardo Campos-Chávez3, Kees C. L. C. M. Franken4, Tom H. M. Ottenhoff4,
Juraj Ivanyi5 and Clara Espitia1,5*
1 Departamento de Inmunologı́a, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México,
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T cells recognizing epitopes on the surface of mycobacteria-infected macrophages can
impart protection, but with associated risk for reactivation to lung pathology. We aimed to
identify antibodies specific to such epitopes, which carry potentials for development
toward novel therapeutic constructs. Since epitopes presented in the context of major
histocompatibility complex alleles are rarely recognized by naturally produced antibodies,
we used a phage display library for the identification of monoclonal human single domain
antibody producing clones. The selected 2C clone displayed T cell receptor-like
recognition of an HLA-A*0201 bound 199KLVANNTRL207 peptide from the Ag85B
antigen, which is known to be an immunodominant epitope for human T cells. The
specificity of the selected domain antibody was demonstrated by solid phase
immunoassay and by immunofluorescent surface staining of peptide loaded cells of the
T2 cell line. The antibody affinity binding was determined by biolayer interferometry. Our
results validated the used technologies as suitable for the generation of antibodies against
epitopes on the surface of Mycobacterium tuberculosis infected cells. The potential
approaches forward the development of antibody in immunotherapy of tuberculosis
have been outlined in the discussion.
Keywords: tuberculosis, single domain antibodies, peptide-human leukocyte antigen complex, mycobacterial
Ag85B, T cell receptor-like antibodiesINTRODUCTION
Current problems of Tuberculosis (TB) control are due to the emergence of drug resistant strains,
the failure of the existing BCG vaccination and the persistence of factors associated with poverty-
stricken populations. Consequently, there is a global morbidity of 10 million people with the
mortality of 1.2 million in HIV-negative people and 0.25 million in HIV positive subjects (1) Neworg October 2020 | Volume 11 | Article 5778151
Ortega et al. sdAb Against M. Tuberculosis Peptide HLA-A*0201approaches toward the control of TB involve the shortening of
the current chemotherapy regimen (2) and prophylaxis for HIV-
related TB without interfering with antiretroviral therapy (3).
This pilot study, aiming at the immunotherapy of TB had an
initial objective to identify monoclonal antibodies with T cell
receptor (TCR)-like specificity, binding to peptide epitope/
human leukocyte antigen (HLA) class I complexes on the
surface of M. tuberculosis infected cells. This approach has
been based in the evidence, that such antibodies can be
developed for the specific killing of malignant and virus-
infected cells (4–10).
The mycobacterial peptides epitopes complexed with MHC
class I molecules on the surface of infected cells are known to be
recognized and leading to the activation of CD8+ T cells (11–13).
Therefore, antibodies with TCR-like specificity following
conjugation with suitable apoptosis-inducing ligands could
potentially become mycobactericidal and a suitable adjunct to
the chemotherapy of TB. The identification of TCR-like
antibodies with specificity against M. tuberculosis Acr1
peptides/HLA.A*0201, HLA.A*011 and HLA.A*24 class I
complexes has recently been reported, using peptide/MHC
complexes generated via UV-induced peptide exchange.
The complexes were panned against human DAb (domain
antibody) phage display library (14, 15). This approach can be
expanded by testing immunodominant epitopes from other M.
tuberculosis antigens recognized in the context of HLA class I
alleles (16, 17). Our interest focused on the HLA-A*0201
restricted CD8+T-cell epitopes of Ag85B, a major secreted M.
tuberculosis protein. Two Ag85B peptides 143FIYAGSLSA151 and
199KLVANNTRL207 had previously been identified in healthy
humans and in immunized HLA-A2 transgenic mice (18), while
HLA-A*0201 allele specific recognition of 37YLLDGLRAQ45 and
199KLVANNTRL207, was observed in patients with active TB
(19). Since epitopes from Esat-6 and TB10.4, are recognized in
the context of various HLA-A alleles, the HLA-A*0201
restricted, 199KLVANNTRL207 epitope from Ag85B appeared
to be the most immunodominant (17) and was therefore
chosen as our target for the selection and characterization of a
TCR-like antibody. Using a human DAb phage display library,
we selected a clone producing a single domain antibody (sdAb)
against the Ag85Bp199-207/HLA-A*0201 complex (Ag85Bp/HLA-
A*0201). Its specificity was determined by ELISA, and by its
binding capacity to the Ag85Bp/HLA-A*0201 expressed on cells
of the human HLA-A*0201 positive T2 cell line.MATERIALS AND METHODS
Mycobacterium tuberculosis Peptides/
HLA-A*0201 Complexes
Three nonamer peptides, known to be HLA-A*0201 restricted
CD8+T cell epitopes from: Ag85B (199KLVANNTRL207), Esat-6
(82AMASTEGNV90), or Acr1 (120GILTVSVAV128) proteins of
M. tuberculosis (16) were synthesized by Anaspec, Inc. (USA).
The peptides were of > 90% purity, and their homogeneity was
confirmed by analytical reverse-phase high-performance liquidFrontiers in Immunology | www.frontiersin.org 2chromatography. The biotinylated recombinant complexes of
Ag85Bp/HLA-A*0201, Esat-6p82-90/HLA-A*0201 (Esat-6p/
HLA-A*0201), and Acr1p120-128/HLA-A*0201 (Acr1p/HLA-
A*0201), were produced using extracellular HLA class I
molecules, with C-terminal BirA recognition site, and b2-
microglobulin (20). The insoluble aggregates expressed in
Escherichia coli in the form of inclusion bodies were
solubilized in urea and folded with peptide by dilution.
Monomers were biotinylated using the BirA enzyme and
purified by gel filtration on a Hiload 16/60 Superdex 75
prep grade.
Evaluation of Refolding of Peptide/HLA-
A*0201 Complexes by ELISA
An ELISA was carried out to evaluate the correct conformation of
the complexes by using the W6/32 mAb (Invitrogen/USA) which
recognizes a conformational epitope on the intact heavy chain/
b2microglobulin complex (21–23). Briefly, 0.5 mg/well of the
biotinylated complexes in Phosphate Buffer Saline (PBS), were
immobilized on streptavidin coated (ThermoScientific/USA) and
on uncoated high protein-binding (ThermoScientific) plates.
Samples were incubated overnight (ON) at 4°C. Next day, plates
were washed twice with PBS and then incubated 1 h at room
temperature (RT) withW6/32 mAb diluted 1/2,000 in PBS-tween-
20 0.05%, Bovine Serum Albumin BSA 2% (PBS-TBSA). After 3
washes with PBS-T, wells were incubated by 1 h with Horseradish
peroxidase conjugated goat anti-mouse IgG H+L antibody (anti-
mouse IgG-HRP)[1/2,000 (Invitrogen/USA)]. Then, complexes on
both streptavidin coated and uncoated plates, were incubated with
streptavidin-HRP (Biosource/China), diluted 1/4,000 1 h at RT.
Finally the reaction was revealed with TMB (3,3’,5,5’-
tetramethylbenzidine) (ThermoScientific), and stopped with
100 ml of 0.16M H2SO4. Absorbance values were measured at
450 nm using an ELISA plate reader (Multiskan Go, Thermo).
Panning of the Human Single Domain
Antibody Phage Library Against the
Ag85Bp199-207/HLA‐A*0201 Complex
A human DAb phage display library, containing approximately
3×109 sdAb clones (Geneservice, Cambridge) was used following
a modified protocol (24). A negative panning was carried out for
elimination of the background reactivity against streptavidin as
follow: 5 x1012 phage library particles were pre-incubated at 4°C
for 1h with 30 ml of streptavidin magnetic beads M280
(Invitrogen/Norway), then tube was placed in a magnet and
phage supernatant was incubated with a 7.5 mg of biotinylated
Ag85Bp/HLA-A*0201 in PBS at 4°C for 1h. After that, 200 ml of
streptavidin beads were added and sample was incubated for
15 min at 4°C with shaking. Beads were pulled down with the
magnet and washed 15 times with PBS-T 0.1%. Finally, sdAb
phage complexes were eluted by incubation with glycine–HCl
pH 2.2 for 15 min at RT and sample was neutralized with Tris-
HCl pH 9.0. For the second and the third round of selection, 2.5
and 1.25 mg of complexes were exposed to streptavidin beads and
washed 15 and 25 times with PBS-T 0.1% respectively. After the
third final round of panning, the eluted sdAb phages were usedOctober 2020 | Volume 11 | Article 577815
Ortega et al. sdAb Against M. Tuberculosis Peptide HLA-A*0201to infect 5 ml freshly prepared E. coli TG1 culture. Bacteria were
plated onto TYE medium supplemented with 4% glucose and
carbenicillin 100 mg/ml (TYG4%C100). After ON culture, 94
individual clones were picked onto a 96 wells plate, containing
200 ml of 2xTYG4%C100. Plates were incubated ON at 37°C, with
shaking at 200 rpm. Next day, 5 ml of ON culture from each well
was transferred to a new plate with 200 ml of fresh 2xTYG4%C100.
After 3 h of culture at 37°C, 50 ml 2xTY supplemented with 4x108
M13 phage was added to each well and plates were incubated for
1 h at 37°C. After centrifugation to 2,800 rpm during 10 min,
pellet was re suspended in 200 ml of 2xTYC100K100 (Kanamycin
100 mg/ml). Cultures were grown at 26°C with shaking at 250
rpm, during 16-24 h.
ELISA Phage
Phage supernatants from each well were collected and evaluated
by ELISA. Biotinylated complexes at 0.5 mg/well were bound to
coated streptavidin plates as described before, and incubated
with 100 ml of phage supernatant for 1 h at RT. After several
washes with PBS-T 0.05%, wells were incubated with anti-M13
HRP antibody (1/2,500) for 1 h at RT (GE Healthcare/USA). The
reac t ion was deve loped wi th o-Pheny lenediamine
dihydrochloride OPD (SigmaAldrich/USA), and stopped
adding 25 ml of 3M H2SO4. Absorbance values were measured
at 492 nm using an ELISA plate reader Multiskan–GO. Phage
supernatants from positive clones were also evaluated by phage
ELISA against non-target complex; Esat-6p/HLA-A*0201 and
Acr1p/HLA-A*0201 as described above.
Domain Antibody Sequencing
Double strand phagemid DNA extraction was performed from 3
selected clones in E. coli strain TG1 by using GeneJET Plasmid
Miniprep kit (ThermoScientific/Lithuania), The primers used for
sequencing were LMB3 (5′ CAGGAAACAGCTATGAC 3′) and
pHEN (5′CTATGCGGCCCCATTCA 3′). Sequencing was
carried out in the sequencing facility at Instituto de
Investigaciones Biomédicas. For translation BioEdit 7.2
software was used and BLAST and Clustalw tools for
sequences analysis and alignment.
Production of Soluble Domain Antibody
Transformation of E. coli HB2151 by phage infection and
expression of sdAb were done with minor modifications
according to (25). Once bacteria were transformed with
phages, the positive clones (2C, 3C, and 7E), 50 ml of 1:1012 to
1:106 cell dilutions were sub-cultured in TYEC100 plates and
incubated overnight at 37°C. Three random unit forming colony
(UFC) were picked up from each sample and inoculated in a
culture flask containing 2xTYC100. The culture was grown with
shaking (250 rpm) at 37°C until OD600nm=0.6 (26). Then,
Isopropyl-b-D-1-thiogalactoside (IPTG) (Promega/USA) was
added to a final concentration of 1 mM, culture was continued,
at 26°C with shaking (250 rpm), ON. Cells were harvest by
centrifugation at 4,500 rpm, and bacterial sediment was treated
with an osmotic buffer (750 mM sucrose, 100 mM Tris pH 7.5) as
described by (27). The periplasmic fractions obtained from each
clone were subjected to affinity chromatography on Protein-A-Frontiers in Immunology | www.frontiersin.org 3agarose (Roche/Germany), in order to purify the sdAbs following
the manufacturer protocol. The eluted protein fractions were
shuffled and concentrated to 500 ml in PBS pH 7.4, using amicon-
15ml, 10.000 WM (Merck/Ireland). Protein quantification was
determined by BCA assay (Pierce/USA).
SDS-PAGE and Western Blot
Ten mg/well of recombinant periplasmic extracts and 1.4 mg/well
from 2C and 7E clones, were resolved on pre-made SDS-PAGE
4%–20%, (ThermoScientific/USA) and transferred to PVDF
membranes. After 1 h blocking with PBS-BSA at RT,
membranes were incubated with anti-c-Myc mAb (Sigma/
USA) diluted 1/750 in PBS-T-BSA and then after washes with
PBS-T, membranes were incubated with anti-mouse IgG HRP
diluted (1/2,000)(Invitrogen/USA) for 1 h, washed with PBS-T,
and developed with 3 mg/ml of 3,3-diaminobenzidine in PBS
and 30% hydrogen peroxide diluted 1:1,000.
Evaluation of Specificity of Single Domain
Antibodies by ELISA
The specificity of the purified sdAb 2C and 7E, were evaluated by
ELISA using 1mg of target Ag85Bp/HLA-A*0201 and non-
targets Esat-6p/HLA-A*0201 and Acr1p/HLA-A*0201 as
which were immobilized on streptavidin plates. Complexes
were incubated with 5 mg of sdAb followed by incubation with
1/1,000 dilution of anti-c-Myc Ab labelled with HRP (Sigma-
Aldrich/Ireland Ltd) by 1h. After several washes with PBS-T, the
reaction was developed with 50 ml of TMB. The reaction was
stopped with 1M of H2SO4. OD450nm was measured in an
Infinitum F50 microplate ELISA reader (Tecan/Switzerland).
Three experiments were carried out by duplicated for 2C and 2
experiments for 7E.
Ex Vivo Specificity of Single Domain 2C on
the Surface of T2 Cells
To assess the ability to sdAb 2C to recognize the Ag85Bp/HLA-
A*0201 an ex vivo assay was performed, by using the HLA-
A*0201 positive T2 lymphoblastic human cell line (kindly donate
by Dr. Patricia Gorocica INER-México). These cells are
characterized by export empty HLA class I molecules due to a
processing defect by homozygous deletion of the MHC class II
region located on chromosome 6 including the TAP1 and TAP2
(transporters associated with antigen processing) genes which
encode the transporter proteins (28). Cells were maintained in
RPMI-1640 medium supplemented with 20% (vol/vol) fetal
bovine serum (FBS) (Gibco/USA), at 37°C, 5% C02. T2 cells
(6x105) were placed on flat bottom, 24 well cell culture plates
(Costar/USA) in RPMI free serum in absence and presence of
peptides from Ag85B and Esat-6.
In order to confirm the presence of HLA-ABC on T2 cells,
they were incubated with W6/32 mAb (1mg/million cells), for
30 min on ice, after 3 washes, goat anti-mouse IgG Alexa fluor
488 (Invitrogen/USA) at 1/2,000 dilution was added. Samples
were fixating with 0.5% PFA and the slides were mounted with
vectashield (Vector Laboratories/USA). Then, cells (6x105) were
incubated with 80 mg of either Ag85Bp(199-207) target peptide and
Esat-6p(82-90) as non-target. Twenty mg/ml of b2m (Sigma) wasOctober 2020 | Volume 11 | Article 577815
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5% CO2 atmosphere, after that cells were washed twice with PBS
and incubated with 10 mg of sdAb 2C ON at 4°C in agitation, and
then washed 2 times, with PBS, following by incubation with
anti-c-Myc Ab (Santa Cruz-/Europe) (1/100) for 1 h at RT. After
three washes, anti-mouse IgG Alexa fluor 488 (Invitrogen/USA)
(1/2,000) was added and samples were incubated for 1 h at RT.
After three washes, Hoechst 33343 (Life technologies/USA)
diluted 1/9,000 was used for 10 min for nucleus staining. sdAb
2C was evaluated on cells in the absence of peptides and as a
staining control in one condition, no domain was added.
Fluorescence images were acquired with Olympus BX41,
(Fluorescence-Microcopy) using the 100x magnifying lens,
the digital images were captured with Zen 2.6 blue edition
software, and the capture parameters, exposure time and
intensity for each staining system, were applied in both control
and problem samples.
Kinetic Binding Assays for the Assessment
of the Interaction of sdAb 2C With Ag85B/
HLA-A*0201 Complex by Biolayer
Interferometry
The binding kinetics and the determination of the dissociation
constant (KD) for the sdAb 2C against the Ag85Bp/HLA-A*0201
complex were performed using Biolayer Interferometry (BLI) at
25°C. Streptavidin biosensors in an Octet RED96 system (FortéBio
Inc. San Jose, CA, USA) were used. The assays were performed on
black bottom 96-well microplates (Greiner Bio-One 655209) in a
total volume of 200 ml with orbital shaking at 1000 rpm.
Experiments were controlled with the software Data Acquisition
8.2 (ForteBio, Inc.) For the BLI experiment, a baseline was
established using 1x Kinetics buffer (FortéBio Inc. San Jose, CA,
USA). Then, the biotinylated Ag85Bp/HLA-A*0201 complex at 25
ng was allowed to bind to streptavidin sensor for 5 min, followed
by washing with the same buffer to eliminate nonspecific binding.
Next, the purified sdAb was bound to the Ag85Bp/HLA-A*0201
complex in the biosensor and the association rate was measured
(ka). In the last step, the dissociation rate (kd) of the antibody-
complex was obtained. The BLI experiment was done with six
different concentrations of the sdAb 2C from (2.54 to 81.3 mM),
one well with 200 ml without sdAb was used as a negative control.Frontiers in Immunology | www.frontiersin.org 4New streptavidin biosensors were used for each experiment. The
binding of sdAb 2C at 10 mM, to non-target Esat-6p/HLA-A*0201
was also tested. The data were processed using the Octet Data
Analysis Software version 8.2 (FortéBio Inc. San Jose, CA, USA)
according to a 1:1 model.
Statistical Analysis
GraphPad Prism version 6.0c software was used to analyze the
results. For the statistical analysis, one-way ANOVA multiple
comparisons with Sidak`s post Hoc correction was used.RESULTS
Evaluation of Peptide HLA-A Complexes
With W6/32 Antibody
Ag85Bp/HLA-A*0201, Esat-6p/HLA-A*0201, and Acr1p/HLA-
A*0201 immobilized on streptavidin plates were recognized by
W6/32 mAb (Figure 1A), indicating this result that peptides
HLA-A*0201 complexes were correctly folded. In contrast, the
mAb did not recognize the complexes bound to non-coated
streptavidin control plate (Figure 1B), showing the results that
direct binding of the complexes in the plates could lead to a loss
of conformation. The biotinylated complexes bound to
streptavidin plates were not recognized for streptavidin-HRP,
an indication that biotinylated complexes were correctly oriented
by streptavidin on coated plates (Figure 1A). In contrast, the
positive signal obtained with the complexes bound to the non-
coated streptavidin plate (Figure 1B), was an indication that
exposed biotin in unfolded complexes was being recognized by
streptavidin-HRP.
Screening of the Human Single DAb Phage
Library Binding to Ag85Bp199-207 HLA‐
A*0201/Complexes
The number of phage particles from sdAb library during the
three rounds of selection was consistent with the published
protocol (24). The final output titers of phage particles showed
an enrichment factor of 25 (Table 1). From 94 clones evaluated
by monoclonal phage-ELISA, only 7 clones showed absorbance
10 fold higher than the negative control (clone not reactive to theA B
FIGURE 1 | Evaluation of complexes with conformational antibody W6/32. (A) Two groups of biotinylated complexes were immobilized on streptavidin coated
plates, the group on the left was detected with W6/32 and the group on the right, was incubated with HRP-streptavidin. (B) The same as A, but both groups of
biotinylated complexes were bound to uncoated streptavidin plates and detected with W6/32 and HRP-streptavidin respectively. The dates represent the media +/-
standard deviation from three independent experiments.October 2020 | Volume 11 | Article 577815
Ortega et al. sdAb Against M. Tuberculosis Peptide HLA-A*0201Ag85Bp/HLA-A*0201) (Figure 2A). From those, clones 2C, 3C,
and 7E did not recognized streptavidin (Figure 2B) and all of
them showed specific binding by ELISA to the target complex
and but none bound to non-target complexes, Esat-6p/HLA-
A*0201, and Acr1p/HLA-A*0201 (Figure 2C).
Domain Antibody Sequencing
BLAST search analysis of sdAb 2C, 3C, and 7E sequences,
showed that all them matched with 122 amino acids length of
immunoglobulin heavy chain variable region, partial
(>ABM67233.1 Homo sapiens). Sequences corresponded to a
human dAb with a length of 160 and 159 amino acids residues
for 2C and 7E domains, respectively, the protein sequence of the
3C domain was exactly the same as 2C but shorter in length, 3C
had only 151 amino acids due to the presence of a stop codon.
For all sequences, the three complementarity determining
regions (CDR) and the c-Myc tag sequence were identified.
Clones 2C and 7E were selected to continue with de antibody
expression phase.Frontiers in Immunology | www.frontiersin.org 5Production of Single Domain Antibodies
sdAb 2C was produced in E. coli HB2151. The expression and
purification of sdAb 2C is shown in Figure 3A. Purified sdAb 2C
with the expected molecular mass of ≈15 kDa was detected by
Coomassie blue staining (Figure 3A, line 3) and antibody was
recognized by anti-c-Myc Ab on Western blot (Figure 3A, line
4). The yield of production of 2C was 1418 µg from 50 ml of
culture, (Results obtained with 7E are not shown).
Specificity of Single Domain Antibodies by
ELISA
The recognition of the Ag85Bp/HLA-A*0201 complex by sdAb
2C was evaluated by ELISA, using Esat-6p/HLA-A*0201 and
Acr1p/HLA-A*0201 as non-targets. The results are shown in
Figure 3B. The binding of sdAb 2C to Ag85Bp/HLA-A*0201
complex was highly specific, showing statistically significant
differences with respect to non-targed complexes. On the other
hand, sdAb 7E, showed a nonspecific signal absorbance ratios for
both target and non-target complexes (Results not shown).TABLE 1 | Selective enrichment of phage domain antibody after 3 rounds of biopanning.
SelS Selection
Round
Ag85Bp/
HLA-A*0201
Phages Input Eluted
phages/ml
Eluted/input Enrichment
Factor*
Amplified
Phages/ml
Tween 20/ #
washes
1 7.5mg 5.0×1012 6.0×106 1.2×10-6 1.0 84×1012 1.0%/15
2 2.5mg 5.0×1012 1.4×108 2.8×10-5 23 7×1012 0.1%/15
3 1.25mg 5.0×1012 1.5 ×108 3.0×10-5 25 — 0.1%/25October 2020 | Volume 11 | A*Enrichment factor was determined by dividing the eluted/input ratio in each round by the ratio in the first round. according to Bagheri et al. (30) Zhang et al. (31).A
B C
FIGURE 2 | Monoclonal phage-domain Immunoassay. (A) Clones from the third round of panning. Positives clones showed signal recognition to Ag85Bp/HLA-
A*0201 of 10 fold higher than negative control (NC), well with unrelated sdAb. Line indicates the threshold used to define a positive result. (B) Positive clones
exposed to streptavidin coated plates (without complex). (C) Clones 2C, 3C, and 7E that showed the lowest recognition signal towards streptavidin tested with non-
target peptides.rticle 577815
Ortega et al. sdAb Against M. Tuberculosis Peptide HLA-A*0201Ex Vivo Specificity of Soluble Domain 2C
on T2 Cells Surface
Surface expression of HLA-A molecules in T2 cells was
demonstrable by binding of the W6/32 mAb in absence and in
presence of either Ag85Bp199-207 or Esat-66p82-90 peptides
(Supplementary Figure S1). However, sdAbs 2C showed
different recognition patterns, whereby the sdAb 2C fluorescence
signal was observed only on T2 cells exposed to the Ag85Bp199-207
(Figure 4). About 6.4% of positive events were observed, but no
positive signals were detected without sdAb 2C, or without
Ag85Bp199-207, or by incubation with the no-target Esat-6 peptide.
sdAb 2C Binding Affinity by Biolayer
Interferometry
The association of sdAb 2C to Ag85Bp/HLA-A*0201 was
measured by BLI. The affinity constant was calculated in terms
of equilibrium dissociation constant (KD) to be 15 + 0.20 mM
(Figure 5A). The sdAb interacts with the target complex in a
concentration dependent manner and confirms the dissociation
constant value (Figure 5B). The interaction of sdAb with Esat-
6p/HLA-A*0201 was very low and the binding parameters could
not be determined.DISCUSSION
CD8+ T cells recognizing peptide epitopes bound to MHC/HLA
class I molecules have the capacity to lyse the M. tuberculosis
infected cells, thus contributing to the intracellular killing of the
infecting organisms (16). Hence, binding of antibodies with
TCR-like recognition specificity seemed desirable for developing
antibody constructs, with mycobactericidal potentials. TCR-like
Ab recognizing MHC class I bound antigenic peptides on
antigen presenting cells, have previously been reported for the
treatment of cancer, viral infections and autoimmune diseases
(6). The aim toward TB immunotherapy has recently beenFrontiers in Immunology | www.frontiersin.org 6initiated by the selection of antibodies against the latency
expressed Acr1/HLA class I restricted epitopes (14, 15). We
report here on a TCR-like sdAb against an immunodominant
HLA-A*0201 binding epitope of the Ag85B, selected by
screening and selection from a human DAb phage display
library. The secreted, fibronectin binding, mycolyl transferase
protein is a strong immunogen in both infected and active TB
cases and it has been used in several recombinant vaccine
constructs (32–35). We chose the p199KLVANNTRL207
peptide as the target epitope in this study, because its known
immunodominance for the human CD8+ T cell responses in the
context of HLA-A*0201 and it’s a conserved sequence in the
genome (16, 17, 19). These properties favoured the previous
application of TCR-like sdAbs for targeting tumors and cells
infected with other pathogens (36, 37).
The procedures used for the selection and evaluation of TCR-
like sdAbs ensure the specificity of recognition between for the
target and non-target molecules. In this work, all the biotinylated
complexes were first evaluated through a comparative ELISA,
using plates with or without streptavidin. The results showed
that the streptavidin coated plates ensured an adequate
arrangement and orientation of p/HLA-A complexes, which is
necessary for finding the specific TCR-like sdAbs. Similarly,
Ag85Bp/HLA-A*0201 was bound to magnetic pearl cover with
streptavidin for the selection of recombinant phages (26). From
the third-round of selection, clones, 2C and 3C of identical
sequence and clone 7E bound to the target complex. However,
after conversion to the soluble form, sdAb 7E lost its specificity
for the target complex. Such a change in specificity was
previously reported to be due to loss of structural support by
the phage scaffold pIII protein for the anti-H1N1 influenza virus
antibody’s antigen-binding site (38). The production of sdAb 2C
and 7E in E. coli HB2151 from periplasmatic extracts was
satisfactory, compared with the previously reported production
outputs (25, 39).
Although sdAb 2C was highly specific against the target
complex, its affinity is low, i.e., in the range of 1–100 mMA B
FIGURE 3 | Expression, purification and specificity evaluation of sdAb 2C. (A) Lanes 1 to 3. Line 1, Coomassie blue stained of periplasmatic extract. Line 2,
unbound fraction to protein A sepharose column. Line 3, purified domain. Lane 4, Western blot of purified sdAb 2C recognized by anti-c-Myc Ab. (B) Evaluation of
specificity of sdAb 2C by ELISA with target Ag85Bp/HLA-A*0201 and non-target (Esat-6p/HLA-A*0201 and Acr1p/HLA-A*0201) complexes. The results represent 3
independent experiments and significant differences are indicated by asterisk (p < 0.05).October 2020 | Volume 11 | Article 577815
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FIGURE 5 | Real-time biolayer interferometry sensorgrams for determination of the binding affinity. (A) Sensorgram showing reference substrate binding, on
streptavidine biosensors, of Ag85Bp/HLA-A*0201 complex with increased concentrations of sdAb 2C. Calculated affinity constant KD is shown in the upper right of
the sensorgram. Association constant, ka: 1.93 × 10
4 + 0.02 × 104 M-1 s-1; dissociation constant, kd: 0.289 + 0.003 s
-1. (B) Steady state analysis of the binding
response (nm) as a function of sdAb. Calculated KD 15.0 + 0.7 mM.FIGURE 4 | Recognition of M. tuberculosis peptide/HLA-A*0201 complex on T2 cells surface by sdAb 2C. Cells were exposed to Ag85B and Esat-6 peptides. As
negative control cells without peptide were used. Peptide/HLA-A*0201complexes were detected with sdAb 2C follow by anti-IgG coupled to Alexa Fluor 488 as
secondary Ab. More than 200 fields were examined for each condition using the 100x magnification, by fluorescence microscopy.Frontiers in Immunology | www.frontiersin.org October 2020 | Volume 11 | Article 5778157
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The low binding affinity known for TCR-like antibody fragments
selected from human libraries can be improved using
complementary technologies (40). An increased up to 100 fold
of the initial affinity from scFv (single chain variable fragment)
directed against the HLA-A2-pWT1126 complex, was achived by
mutagenesis combined with yeast display based on one specific
scFv-clone (41). The affinity could also be improved by re-
cloning and re-selection of clones or by conversion of sdAbs
into multivalent formats with higher avidity (4, 42). Though
antibody affinity can be significant for its potential for
immunotherapy, most interestingly however, it was found that
low, rather than high antibody affinity has been reported to
essential for the passive antibody therapy of a drosophila based
model of Alzheimer’s disease (43, 44). This was interpreted on
the grounds that the low affinity anti-tau antibody may loosen up
intracellular tau aggregates allowing better access of lysosomal
degrading enzymes, while high affinity antibody may make these
aggregates more compact and therefore more difficult to
degrade. Such interpretation may be relevant also for the
desired intracellular mycobactericidal action on M. tuberculosis
infected macrophages.
Antibodies generated in animals against MHC-I recombinant
tetramers are rarely TCR-like, because many of them recognize
the a3 domain of MHC-I and b2 microglobulin (b2m) (5) and
also due to the reduced stability of recombinant p/HLA-A
complex (45). However, the phage display antibody libraries
have the advantage that the fusion proteins are exposed on the
surface of phage particles, and recombinant p/HLA-A complex
targets can be used through several selection rounds (37). The
structure of human sdAbs also known as nanobodies, used in
the present work represents a single variable domain based on
the VH3-23 germline segment heavy chain with synthetic
diversity introduced by PCR mutagenesis into all tree
complementary determining regions (24). They are highly
stable, easily produced in large quantity by E. coli, they are of
low immunogenicity, small size (15 kDa), and can be fused
with multiple tags (46–48). Consequently, sdAbs have been
used for virus detection (49–51), for imaging in vivo, mainly in
cancer due to their bio distribution, high tumor penetrance
and fast clearance from the blood circulation (52). The
immunotherapeutic potentials include therapeutic targets in
cancer (53), antagonism of angiogenesis (54) and acting as
metastasis inhibitors.CONCLUSIONS AND PERSPECTIVES
The TCR-like identity of the sdAb 2C has been validated by its
specific recognition of Ag85Bp/HLA-A*0201 on the surface of
human T2 cell line. It will be of further interest to test, if the sdAb
2C can detect the expression of the HLA-A*0201-bound Ag85B
peptide on humanmacrophages, which contain either replicating
or dormant M. tuberculosis infection. A positive result would
justify further engineering of the sdAb 2C to become anFrontiers in Immunology | www.frontiersin.org 8immunotoxin, by conjugation with suitable apoptosis inducing
ligands, i.e., Pseudomonas exotoxin A, Granzyme B or BH3
peptide (55, 56), in endeavour to develop a mycobactericidal
immunotherapeutic agent.
Further, development of sdAb 2C will need evaluation in both
HLA-A*0201 transgenic mice and in humans with active TB
disease. The obtained results are showing the feasibility of
selecting TCR-like sdAbs to other immunodominant epitopes
of M. tuberculosis and their future development as potential
immunotherapeutic adjuncts to the chemotherapy of TB.DATA AVAILABILITY STATEMENT
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